NervGen Pharma Corp.
NGEN
$2.13
-$0.06-2.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.21M | 7.90M | 7.99M | 7.56M | 8.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.08M | 19.17M | 17.95M | 18.22M | 19.04M |
| Operating Income | -23.08M | -19.17M | -17.95M | -18.22M | -19.04M |
| Income Before Tax | -44.10M | -30.10M | -31.65M | -18.50M | -19.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -44.10 | -30.10 | -31.65 | -18.50 | -19.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.10M | -30.10M | -31.65M | -18.50M | -19.36M |
| EBIT | -23.08M | -19.17M | -17.95M | -18.22M | -19.04M |
| EBITDA | -23.04M | -19.13M | -17.91M | -18.18M | -19.00M |
| EPS Basic | -0.54 | -0.41 | -0.43 | -0.26 | -0.27 |
| Normalized Basic EPS | -0.34 | -0.26 | -0.27 | -0.16 | -0.17 |
| EPS Diluted | -0.63 | -0.46 | -0.44 | -0.26 | -0.28 |
| Normalized Diluted EPS | -0.34 | -0.26 | -0.27 | -0.16 | -0.17 |
| Average Basic Shares Outstanding | 319.02M | 298.53M | 289.30M | 285.78M | 282.68M |
| Average Diluted Shares Outstanding | 320.32M | 299.49M | 289.30M | 285.78M | 282.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |